PH12014501804A1 - Cycloalkane derivative - Google Patents
Cycloalkane derivativeInfo
- Publication number
- PH12014501804A1 PH12014501804A1 PH12014501804A PH12014501804A PH12014501804A1 PH 12014501804 A1 PH12014501804 A1 PH 12014501804A1 PH 12014501804 A PH12014501804 A PH 12014501804A PH 12014501804 A PH12014501804 A PH 12014501804A PH 12014501804 A1 PH12014501804 A1 PH 12014501804A1
- Authority
- PH
- Philippines
- Prior art keywords
- group
- alkyl group
- alkoxy
- alkyl
- halogenated
- Prior art date
Links
- 150000001924 cycloalkanes Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012025754 | 2012-02-09 | ||
| JP2012259122 | 2012-11-27 | ||
| PCT/JP2013/052985 WO2013118854A1 (ja) | 2012-02-09 | 2013-02-08 | シクロアルカン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12014501804A1 true PH12014501804A1 (en) | 2014-11-17 |
| PH12014501804B1 PH12014501804B1 (en) | 2014-11-17 |
Family
ID=48947609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014501804A PH12014501804B1 (en) | 2012-02-09 | 2014-08-11 | Cycloalkane derivative |
| PH12015502675A PH12015502675A1 (en) | 2012-02-09 | 2015-11-27 | Cycloaklane derivative |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015502675A PH12015502675A1 (en) | 2012-02-09 | 2015-11-27 | Cycloaklane derivative |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8889741B2 (enExample) |
| EP (2) | EP2813491B1 (enExample) |
| JP (2) | JP5997710B2 (enExample) |
| KR (1) | KR20140127238A (enExample) |
| CN (1) | CN104185629B (enExample) |
| AU (1) | AU2013218592B2 (enExample) |
| BR (1) | BR112014019478A2 (enExample) |
| CA (1) | CA2864222C (enExample) |
| CO (1) | CO7151511A2 (enExample) |
| CY (1) | CY1118572T1 (enExample) |
| DK (1) | DK2813491T3 (enExample) |
| ES (2) | ES2659434T3 (enExample) |
| HR (1) | HRP20161713T1 (enExample) |
| HU (2) | HUE031450T2 (enExample) |
| IL (1) | IL234014A (enExample) |
| IN (1) | IN2014MN01577A (enExample) |
| LT (1) | LT2813491T (enExample) |
| MX (1) | MX349354B (enExample) |
| NZ (1) | NZ628096A (enExample) |
| PH (2) | PH12014501804B1 (enExample) |
| PL (1) | PL2813491T3 (enExample) |
| PT (1) | PT2813491T (enExample) |
| RS (1) | RS55671B1 (enExample) |
| RU (1) | RU2635354C2 (enExample) |
| SG (1) | SG11201404707VA (enExample) |
| SI (1) | SI2813491T1 (enExample) |
| SM (2) | SMT201700053T1 (enExample) |
| TW (1) | TWI612042B (enExample) |
| WO (1) | WO2013118854A1 (enExample) |
| ZA (1) | ZA201405801B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9630929B2 (en) * | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| KR101719893B1 (ko) | 2012-05-22 | 2017-03-24 | 제넨테크, 인크. | Ｎ-치환된 벤즈아미드 및 통증의 치료에서 이들의 용도 |
| JP6309519B2 (ja) | 2012-07-06 | 2018-04-11 | ジェネンテック， インコーポレイテッド | Ｎ置換ベンズアミド及びその使用方法 |
| KR20150126620A (ko) * | 2013-03-14 | 2015-11-12 | 다이이찌 산쿄 가부시키가이샤 | 호흡기 질환용 약 |
| WO2014153037A1 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Substituted triazolopyridines and methods of use thereof |
| EP2970156B1 (en) | 2013-03-15 | 2018-07-25 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| AU2014356967A1 (en) | 2013-11-27 | 2016-07-07 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| MA42118A (fr) | 2015-05-22 | 2018-03-28 | Genentech Inc | Benzamides substitués et leurs méthodes d'utilisation |
| WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| MX386501B (es) | 2015-09-28 | 2025-03-19 | Genentech Inc | Compuestos terapeuticos y sus metodos de uso |
| HK1252869A1 (en) * | 2015-11-06 | 2019-06-06 | Daiichi Sankyo Company, Limited | Method for removing dimethoxybenzyl |
| EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| US10766858B2 (en) | 2016-03-30 | 2020-09-08 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| HUE071358T2 (hu) | 2016-05-20 | 2025-08-28 | Xenon Pharmaceuticals Inc | Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk |
| JP2019532077A (ja) * | 2016-10-17 | 2019-11-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| MA46615A (fr) * | 2016-10-27 | 2019-09-04 | Bristol Myers Squibb Co | Inhibiteurs de nav1.7 de type acyl-sulfonamide |
| JP7022751B2 (ja) * | 2016-12-09 | 2022-02-18 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 |
| CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
| AU2018338098B2 (en) | 2017-09-20 | 2024-02-22 | Abm Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| AR114263A1 (es) * | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| EP3774801A1 (en) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| SG11202011862PA (en) | 2018-06-13 | 2020-12-30 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| CN112638898B (zh) | 2018-08-31 | 2024-04-09 | 泽农医药公司 | 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
| JP2022515630A (ja) * | 2018-12-26 | 2022-02-21 | ラクオリア創薬株式会社 | Ｎａｖ１．７およびＮａｖ１．８遮断薬としての複素環誘導体 |
| US20240241265A1 (en) * | 2023-01-18 | 2024-07-18 | Qualcomm Incorporated | Virtual positioning signal measurements |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6222048B1 (en) | 1995-12-18 | 2001-04-24 | Merck Frosst Canada & Co. | Diaryl-2-(5H)-furanones as Cox-2 inhibitors |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| US7745629B2 (en) * | 2005-05-16 | 2010-06-29 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
| US8124610B2 (en) | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
| WO2010035166A1 (en) | 2008-09-23 | 2010-04-01 | Pfizer Limited | Benzamide derivatives |
| HRP20150355T1 (hr) | 2009-01-12 | 2015-06-19 | Pfizer Limited | Sulfonamidni derivati |
| US9145407B2 (en) * | 2010-07-09 | 2015-09-29 | Pfizer Limited | Sulfonamide compounds |
| EP2590957B1 (en) | 2010-07-09 | 2014-11-12 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| CA2804593C (en) * | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
| US9630929B2 (en) * | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
-
2013
- 2013-01-31 US US13/756,173 patent/US8889741B2/en active Active
- 2013-02-07 TW TW102104725A patent/TWI612042B/zh not_active IP Right Cessation
- 2013-02-08 RS RS20170101A patent/RS55671B1/sr unknown
- 2013-02-08 HU HUE13746373A patent/HUE031450T2/en unknown
- 2013-02-08 LT LTEP13746373.3T patent/LT2813491T/lt unknown
- 2013-02-08 SI SI201330423A patent/SI2813491T1/sl unknown
- 2013-02-08 NZ NZ628096A patent/NZ628096A/en not_active IP Right Cessation
- 2013-02-08 HR HRP20161713TT patent/HRP20161713T1/hr unknown
- 2013-02-08 HU HUE16193142A patent/HUE037048T2/hu unknown
- 2013-02-08 EP EP13746373.3A patent/EP2813491B1/en active Active
- 2013-02-08 RU RU2014136463A patent/RU2635354C2/ru not_active IP Right Cessation
- 2013-02-08 PL PL13746373T patent/PL2813491T3/pl unknown
- 2013-02-08 ES ES16193142.3T patent/ES2659434T3/es active Active
- 2013-02-08 KR KR1020147021798A patent/KR20140127238A/ko not_active Abandoned
- 2013-02-08 SM SM20170053T patent/SMT201700053T1/it unknown
- 2013-02-08 SG SG11201404707VA patent/SG11201404707VA/en unknown
- 2013-02-08 JP JP2013557586A patent/JP5997710B2/ja not_active Expired - Fee Related
- 2013-02-08 ES ES13746373.3T patent/ES2613078T3/es active Active
- 2013-02-08 AU AU2013218592A patent/AU2013218592B2/en not_active Ceased
- 2013-02-08 MX MX2014009637A patent/MX349354B/es active IP Right Grant
- 2013-02-08 BR BR112014019478A patent/BR112014019478A2/pt not_active Application Discontinuation
- 2013-02-08 CA CA2864222A patent/CA2864222C/en not_active Expired - Fee Related
- 2013-02-08 EP EP16193142.3A patent/EP3144300B1/en not_active Not-in-force
- 2013-02-08 IN IN1577MUN2014 patent/IN2014MN01577A/en unknown
- 2013-02-08 PT PT137463733T patent/PT2813491T/pt unknown
- 2013-02-08 CN CN201380017715.1A patent/CN104185629B/zh not_active Expired - Fee Related
- 2013-02-08 DK DK13746373.3T patent/DK2813491T3/en active
- 2013-02-08 WO PCT/JP2013/052985 patent/WO2013118854A1/ja not_active Ceased
-
2014
- 2014-08-06 ZA ZA2014/05801A patent/ZA201405801B/en unknown
- 2014-08-07 IL IL234014A patent/IL234014A/en not_active IP Right Cessation
- 2014-08-11 PH PH12014501804A patent/PH12014501804B1/en unknown
- 2014-09-05 CO CO14195847A patent/CO7151511A2/es unknown
- 2014-09-30 US US14/502,708 patent/US9493448B2/en not_active Expired - Fee Related
-
2015
- 2015-11-27 PH PH12015502675A patent/PH12015502675A1/en unknown
-
2016
- 2016-08-26 JP JP2016165515A patent/JP6154052B2/ja not_active Expired - Fee Related
- 2016-09-19 US US15/269,485 patent/US9845313B2/en not_active Expired - Fee Related
-
2017
- 2017-01-24 SM SM201700053T patent/SMT201700053B/it unknown
- 2017-01-31 CY CY20171100142T patent/CY1118572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501804A1 (en) | Cycloalkane derivative | |
| IN2014DN03063A (enExample) | ||
| PH12016501028A1 (en) | Prodrugs of pyridone amides useful as modulators of sodium channels | |
| NZ703064A (en) | Inhibitors of hepatitis c virus | |
| JO3453B1 (ar) | مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1 | |
| PH12016500553A1 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors | |
| MD20160078A2 (ro) | Inhibitori ai Syk | |
| MX2014013957A (es) | Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia). | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| MD20150075A2 (ro) | Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| MX2014006366A (es) | Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo. | |
| MX341341B (es) | Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90). | |
| MX2016007440A (es) | Inhibidores del bromodominio. | |
| PH12015502429A1 (en) | Dicarboxylic acid compound | |
| GEP20207070B (en) | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | |
| MY195177A (en) | Pyrazole Derivative or Pharmaceutically Acceptable Salt Thereof | |
| MX2019010756A (es) | Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). | |
| MX379704B (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida | |
| MX2022006003A (es) | Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia. | |
| RU2015155032A (ru) | Тилозиновые производные и способ их получения | |
| MX2015015485A (es) | Derivado de glicinamida alfa-sustituida. | |
| PH12016501645A1 (en) | Aminopyrazolone derivative | |
| MY162537A (en) | dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds |